By Dr. James W. Stark

The AAN has announced the launch of an open-access, online  journal called Neurology® Neuroimmunology & Neuroinflammation. This new journal will include research on various areas of neuro-immunology, although multiple sclerosis research will be very prominently featured. We look forward to learning from and working with a journal dedicated exclusively to our subspecialty, especially one published by the premiere neurological organization in the world.

The Tisch MS Research Center presented several posters today at the annual AAN meeting in Philadelphia. These include:

Inhibition of Hyaluronan Synthesis Protects Against EAE by Inducing CXCL12 in the CNS

Andre M. Mueller, Bo Hyung Yoon, Saud A. Sadiq

Summary: Inhibition of a molecule called hyaluronan synthesis is protective in a mouse model of MS by interfering with T-cells and reducing the movement of immune cells into the brain. 

Development of...

By Dr. James W. Stark

As many of you know, Teva Pharmaceuticals has launched a new formulation of their MS medication, Copaxone. This Copaxone is a higher dose of the medicine and is taken three times a week instead of daily. The actual amount of liquid has not changed, however, so there are no differences in the method of injection between the old and new formulations. Clinical trials have been completed and show equal efficacy between the two formulations. The incidence of...

To help fund and raise awareness for the Tisch MS Research Phase I Clinical Stem Cell Trial, we have launched a crowdfunding campaign on Indiegogo. Despite the fact that we have FDA and Institutional Review Board (IRB) approval, the trial still remains in critical need of funding. We are reaching out to all of our patients, supporters and friends to help raise awareness about our campaign. To the extent that you are comfortable, we would greatly appreciate you passing our campaign...